Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA approves Cordis' stent on new delivery system:

This article was originally published in Clinica

Executive Summary

The US FDA has approved for sale Cordis' PMA application for its Bx Velocity coronary stent with a rapid exchange delivery system. The product is to be used to treat abrupt and threatened vessel closure in patients with failed interventional therapy in lesions with diameters in the range of 2.25-4mm. The Bx Velocity stent was originally approved by the FDA on an over-the-wire delivery system last May, says Cordis, a Johnson & Johnson company.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts